Journal
FRONTIERS IN ONCOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.802579
Keywords
breast cancer; circulating tumor cells; circulating tumor DNA; liquid biopsy; immunotherapy; biomarkers
Categories
Ask authors/readers for more resources
Liquid biopsy biomarkers, such as CTCs and ctDNA, are noninvasive diagnostics that can complement current predictive and prognostic tools in breast cancer treatment. They have been applied in evaluating immune therapy response and outcomes, with emerging technologies further advancing their applications.
Liquid biopsy biomarkers, such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), are noninvasive diagnostics that could complement predictive and prognostic tools currently used in the clinic. Recent trials of immunotherapy have shown promise in improving outcomes in a subset of breast cancer patients. Biomarkers could improve the efficacy of immune checkpoint inhibitors by identifying patients whose cancers are more likely to respond to immunotherapy. In this review, we discuss the current applications of liquid biopsy and emerging technologies for evaluation of immunotherapy response and outcomes in breast cancer. We also provide an overview of the status of immunotherapy in breast cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available